The Nature Portfolio aims to enhance the reproducibility of published research by requiring structured and transparent reporting. Authors must provide detailed information on statistical analyses, including sample sizes, statistical tests, assumptions, effect sizes, and P-values. Software and code used in the study must be made available, preferably in a public repository. Data availability statements are required, detailing access to datasets and any restrictions. For studies involving human participants, biological materials, or clinical data, ethical approval must be included in the manuscript. Field-specific reporting guidelines apply, with particular emphasis on life sciences, including study design, fieldwork, and ethical considerations. Information on cell lines, animal studies, and clinical trials is also required. For experiments involving potentially harmful agents or technologies, specific policies apply. Additional requirements include data deposition for techniques like ChIP-seq and Flow Cytometry, along with detailed methodology descriptions. The reporting summary must be completed accurately, with no "not applicable" entries, and should adhere to the Nature Portfolio's Editorial Policies and Checklist. All studies must disclose relevant details, even if negative, to ensure transparency and reproducibility. The summary is a critical part of the submission process, ensuring that all necessary information is provided for peer review and replication of the research.The Nature Portfolio aims to enhance the reproducibility of published research by requiring structured and transparent reporting. Authors must provide detailed information on statistical analyses, including sample sizes, statistical tests, assumptions, effect sizes, and P-values. Software and code used in the study must be made available, preferably in a public repository. Data availability statements are required, detailing access to datasets and any restrictions. For studies involving human participants, biological materials, or clinical data, ethical approval must be included in the manuscript. Field-specific reporting guidelines apply, with particular emphasis on life sciences, including study design, fieldwork, and ethical considerations. Information on cell lines, animal studies, and clinical trials is also required. For experiments involving potentially harmful agents or technologies, specific policies apply. Additional requirements include data deposition for techniques like ChIP-seq and Flow Cytometry, along with detailed methodology descriptions. The reporting summary must be completed accurately, with no "not applicable" entries, and should adhere to the Nature Portfolio's Editorial Policies and Checklist. All studies must disclose relevant details, even if negative, to ensure transparency and reproducibility. The summary is a critical part of the submission process, ensuring that all necessary information is provided for peer review and replication of the research.